Home > Back to Publisher > Report Information

Pain Therapeutics: New Times, New Targets

Drug and Market Development Publishing
July 1, 2006
312 Pages - SKU: DSMD1316511

Abstract Table of Contents Search inside this report Related Reports

D&MD’s new Pain Therapeutics market analysis report focuses on new advances in drug discovery and development. The report provides a background on pain, current therapies and research and development in the area. Profiles of companies with major pain programs include Abbott Laboratories, AstraZeneca, GlaxoSmithKline, GW Pharmaceuticals, Johnson & Johnson, Merck & Co., Neuromed Pharmaceuticals, Novartis, Pfizer, Vernalis, VistaGen Therapeutics, Xenome and more. In-depth interviews with industry leaders provide specific case studies from both biotech and academia that give a sense of what’s really going on in the trenches.

Chapter 1: Executive Summary: Introduction; Current Status of Pain Therapeutics; Current Status of Pain Therapeutics; Pain Therapy Market Dynamics; Conclusions
Chapter 2: Introduction: Scope and Nature of the Report; Format of the Report
Chapter 3: History of Pain Therapeutics: References
Chapter 4: Current Status of Pain Therapeutics: The Nature of Pain; The Neurophysiology of Pain; Pain Pharmacology Today; Pain Assessment; Current Pain Management
Chapter 5: Current Pain Research and Development: Basic Research Concepts and Tools; Pain Research Methodologies; Pain Targets and Compounds; References
Chapter 6: Pain Therapy Market Dynamics: General Observations; Strategic Alliances; Pain Drug R&D Survey
Chapter 7: Company Profiles: Abbott Laboratories; Acadia Pharmaceuticals; Adolor Corporation; AstraZeneca; CeNeS Pharmaceuticals plc; Cognetix, Inc; Corgentech Inc; GlaxoSmithKline; GW Pharmaceuticals; Johnson & Johnson; Merck & Co., Inc; NeurogesX, Inc; Neuromed Pharmaceuticals Inc; NeuroTargets Ltd; Novartis; PainCeptor Pharma Corp; Pain Therapeutics, Inc; Pfizer, Inc; Pharmos Corporation; Renovis, Inc; Rinat Neuroscience Corp; Synt:em; Vernalis; VistaGen Therapeutics, Inc; Xenome Ltd; References
Chapter 8: Interviews with Industry Experts: Franz Hefti, Ph D., Executive Vice President, Drug Development, Rinat Neuroscience; Jeffrey S. Mogil, Ph D., E P. Taylor Professor of Pain Studies; Canada Research Chair in Genetics of Pain; Dept. of Psychology and Centre for Research on Pain; McGill University; Corey S. Goodman, Ph D., President, CEO, and Director, Renovis; Remi Barbier, President, CEO, Chairman, Pain Therapeutics, Inc; Neil Kurtz, M D., President and CEO of TorreyPines Therapeutics
Chapter 9: Concluding Comments
Table Of Exhibits: Exhibit 4.1. Categories of Pain; Exhibit 4.2. The Four Processes of Nociception; Exhibit 4.3. Categorization of Analgesics; Exhibit 4.4. Selected NSAIDs Containing Carboxyl Functionality; Exhibit 4.5. Selected NSAIDs Containing Enolic and Phenolic Functionality; Exhibit 4.6. Selected Opioids Categorized by Mode of Action; Exhibit 4.7. Selected Opioids Categorized by Therapeutic Effect; Exhibit 4.8. Descriptive Pain Scale; Exhibit 4.9. Numeric and Analog Pain Scales; Exhibit 4.10.. Hospital Medical Procedures for the Years 1994 and 2003 (in thousands); Exhibit 4.11. The World Health Organization Three-Step Analgesic Ladder; Exhibit 4.12.. Estimates of Utilization of Increasingly Invasive Therapies in the Alleviation of. Cancer Pain; Exhibit 4.13.. Key Issues in AIDS Pain Assessment; Exhibit 4.14.. Characteristics of Major Headache Types; Exhibit 4.15. Characteristics of Major Low Back Pain Types; Exhibit 5.1. A Typical Neuron; Exhibit 5.2. Interconnected Neurons; Exhibit 5.3. A Neuronal Synapse; Exhibit 5.4. A Generic Representation of Ion Channels; Exhibit 5.5. A Nicotinic Acetylcholine Ligand-gated Ion Channel; Exhibit 5.6. Examples of Ligand-Gated Ion Channels; Exhibit 5.7. Receptors Coupled Through G-Proteins or Other Indirect Means; Exhibit 5.8. Sodium Channel Modulators in Development; Exhibit 5.9. Glutaminergic Channel Modulators in Development; Exhibit 5.10. TRPV Vanilloid Channel Modulators in Development; Exhibit 5.11. Cholinergic Channel Agonists in Development; Exhibit 5.12. Other Ion Channel Modulators in Development; Exhibit 5.13. Pharmacological Actions Corresponding to Opioid Receptors; Exhibit 5.14. Opioid Receptor Modulators in Development; Exhibit 5.15 Cannabinoid Receptor Modulators in Development; Exhibit 5.16. Miscellaneous GPCR Modulators in Development; Exhibit 5.17. COX-2 Inhibitors in Development; Exhibit 5.18. Nitric Oxide Synthase Modulators in Development; Exhibit 5.19. Therapeutic Antibodies and Peptides in Development; Exhibit 5.20. Compounds with Other.(or Not Designated).Mechanisms in Development; Exhibit 6.1. Recent Deal Activity in Pain Therapeutics; Exhibit 6.2. Organization Type of Survey Respondents; Exhibit 6.3.. Position Designations for Survey Respondents,.by Company Type; Exhibit 6.4. Predominant Training Modality for Respondents; Exhibit 6.5. Target Focus for Those in Basic Research or Early Discovery; Exhibit 6.6. Drug Target Family Focus; Exhibit 6.7. Have Newer Methods of Target Discovery Generated a.Pain Target?; Exhibit 6.8. Therapeutic Indications for Compounds in Discovery or Development; Exhibit 6.9. Level of Satisfaction with Neuropathic Pain Animal Models; Exhibit 6.10. Degree of Confidence That One or More Drugs Highly Effective for Neuropathic. Pain Will Enter the Market in Five Years; Exhibit 6.11. Pain Drug Discovery Budget Projections; Exhibit 7.1. GlaxoSmithKline Pain Drug Pipeline, February 2006; Exhibit 7.2. Merck Pain Drug Pipeline,.February 2006

Pain Therapeutics: New Times, New Targets

Share this report

Other tasks

Research Assistance

Related Markets

Drug Delivery Reports

Free Alert Me service